EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Gilead Sciences has entered a definitive agreement to acquire Tubulis, a Germany-based clinical-stage antibody-drug conjugate (ADC) company. EQT Life Sciences' LSP 7 fund led Tubulis' Series B2 in March 2024 and has exited its minority stake through the sale, having supported the company at board level. The deal represents a strategic bolt-on for Gilead into next-generation ADCs and provides an exit for a private investor.

Analysis

This deal meaningfully accelerates Gilead’s ability to internalize site-specific ADC chemistry and shortens the timeline to generate clinical readthroughs that can re-rate its oncology multiple. Expect near-term P&L and cash flow impact to be modest; the real value realization hinges on 12–36 month clinical readouts and subsequent commercial labeling — one successful ADC can drive peak sales in the high hundreds of millions to low billions, but failures are binary and front-loaded.

Second-order winners include specialized ADC CMOs and analytics providers: Tubulis’ platform will require bespoke payload/linker supply chains and potency-testing capacity, which can drive 10–25% incremental utilization at niche providers within 6–18 months and create bottlenecks (and pricing power) for site-specific conjugation services. Competitors with legacy maytansinoid or auristatin platforms face renewed pressure to either deepen their payload portfolios or pursue partnerships; larger diversified pharma (PFE, RHHBY) may accelerate M&A in narrower ADC niches to avoid being outgunned on novel linker/payload technology.

Tail risks are classical for ADCs—narrow therapeutic index and unexpected safety signals can wipe out valuations quickly; integration execution and reprioritization inside Gilead could delay commercial launches by 12–24 months. Monitor three catalysts: first human efficacy/safety cohorts (3–12 months), CMO capacity announcements (6–12 months), and any pipeline reprioritization memo from Gilead’s management (quarterly cadence).

Key Decisions for Investors

• Initiate a tactical long in GILD (add on 3–10% pullbacks) with a 12–24 month horizon. Rationale: acquisition narrows the clinical gap vs peers; target +20–30% upside if one mid-stage program reads positive in 12 months. Risk: 20–30% downside if ADC safety issues emerge or Gilead reprioritizes spend.
• Buy a conservative options structure: 9–12 month GILD call spread (long ATM call, sell 10–15% OTM call) to finance exposure and cap premium. R/R: limited premium outlay with 2–4x upside if the market re-rates oncology multiple after positive readouts; downside limited to premium paid.
• Pair trade: long GILD / short IMGN (ImmunoGen) for 6–18 months. Rationale: Gilead’s platform acquisition compresses relative value of older ADC tech; hedge overall market moves and capture convergence. Risk: IMGN upside on its own clinical wins — size short to limit portfolio volatility.
• Tactical long on ADC-focused CMOs (e.g., CTLT or LZAGY) for 6–12 months to capture capacity re-pricing; trim into any 10–20% rally. Rationale: bespoke conjugation demand should lift utilization and pricing; downside if Gilead insources or shifts partners.